- Home
- UTL vs KURA Comparison
UTL vs KURA Comparison
Compare UTL & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | UTL | KURA |
|---|---|---|
| Founded | 1984 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Power Generation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 899.9M | 1.0B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | UTL | KURA |
|---|---|---|
| Price | $48.54 | $10.07 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 11 |
| Target Price | ★ $55.00 | $25.00 |
| AVG Volume (30 Days) | 157.6K | ★ 1.8M |
| Earning Date | 02-09-2026 | 11-04-2025 |
| Dividend Yield | ★ 3.76% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.85 | N/A |
| Revenue | ★ $502,000,000.00 | $104,029,000.00 |
| Revenue This Year | $5.98 | $138.16 |
| Revenue Next Year | $7.76 | $67.37 |
| P/E Ratio | $16.78 | ★ N/A |
| Revenue Growth | ★ 1.03 | N/A |
| 52 Week Low | $44.61 | $5.41 |
| 52 Week High | $59.99 | $12.49 |
Technical Indicators
Market Signals| Indicator | UTL | KURA |
|---|---|---|
| Relative Strength Index (RSI) | 42.54 | 39.34 |
| Support Level | $47.25 | $9.68 |
| Resistance Level | $50.66 | $10.78 |
| Average True Range (ATR) | 1.03 | 0.57 |
| MACD | 0.01 | -0.22 |
| Stochastic Oscillator | 22.58 | 6.82 |
Price Performance
Historical ComparisonAbout UTL UNITIL Corporation
Unitil Corp is a holding company, through its subsidiaries it is engaged in the local distribution of electricity and natural gas throughout its service territories in the states of New Hampshire, Massachusetts, and Maine. The Company has two operating and reportable segments: Utility Electric Operations and Utility Gas Operations. Majority of revenue is gained from Electric Segment.
About KURA Kura Oncology Inc.
Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.